Brief: Mustang Bio Announces First Data From Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating Mb-106 Car-T Cell Therapy

Mustang Bio

16/08/2023 13:04

Aug 16 (Reuters) - Fortress Biotech Inc  FBIO.O :
    * MUSTANG BIO ANNOUNCES FIRST DATA FROM ONGOING MULTICENTER
PHASE
1/2 CLINICAL TRIAL EVALUATING MB-106 CAR-T CELL THERAPY
    * MUSTANG BIO INC - SAFETY REVIEW COMMITTEE UNANIMOUSLY
APPROVED
DOSE ESCALATION OF INDOLENT LYMPHOMA ARM
    * MUSTANG BIO INC - ANTICIPATES REQUESTING REGENERATIVE
MEDICINE
ADVANCED THERAPY (RMAT) DESIGNATION FOR WM FROM FDA IN 2024
    * MUSTANG BIO - CURRENTLY NO FDA-APPROVED CAR-T CELL THERAPY
FOR
WM, AND FIRST PATIENT IN PIVOTAL PHASE 2 WM TRIAL IS EXPECTED TO
BE TREATED IN MID-2024

Source text for Eikon:  ID:nGNX1NTSy2 
Further company coverage:  FBIO.O 

 ((reuters.briefs@thomsonreuters.com;))